Anticoagulation in the elderly;Antikoagulation im Alter

Internist

Volumn 51, Issue 11, 2010, Pages 1446-1455

  Harenberg, J ^a   Bauersachs, R ^b   Diehm, C ^c   Lawall, H ^c   Burkhardt, H ^d   Gerlach, H ^e   Darius, H ^f   Voller H ^g   Rabe, E ^h   Wehling, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM DARMSTADT   (Germany)

^c SRH Klinikum   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Praxis fur Gefasserkrankungen   (Germany)

^f Vivantes Clinic   (Germany)

^g Klinik am See   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Anticoagulation; Elderly; Low molecular weight heparin; Renal impairment; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CREATININE; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BED REST; BLEEDING; COMPRESSION GARMENT; CREATININE BLOOD LEVEL; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; POSTOPERATIVE CARE; PROPHYLAXIS; THROMBOEMBOLISM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION TESTS; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS; STOCKINGS, COMPRESSION; THROMBOEMBOLISM; VITAMIN K;

EID: 78650414630     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2702-6     Document Type: Article

References (30)

1. Alikhan R, Cohen AT, Combe S et al (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164:963-968
2. Ansell J, Hirsh J, Hylek E et al (2008) Pharmacology and management of the vitamin k antagonists. Chest 133:160S-198S
3. AWMF-Leitlinien (2009) Prophylaxe der venösen Thromboembolie (VTE). AWMF-Leitlinien-Register Nr. 003/001, http://www.uni-duesseldorf.de/AWMF/ll/003- 001.htm
4. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1-13
5. Fang MC, Chang Y, Hylek EM et al (2004) Advanced age, anticoagulation intensity and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745-752
6. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8:651-745 (Pubitemid 44472247)
7. Gage BF, Waterman MD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke. JAMA 285:2864-2870
8. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism. Chest 133:381S-453S
9. Go AS, Hylek EM et al (2006) Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 54:1231-1236
10. Gould MK, Dembitzer AD, Doyle RL et al (1999) Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130:800-809
11. Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631-639 (Pubitemid 36975995)
12. Kopecky SL, Gersh BJ, McGoon MD et al (1999) Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 159:1118-1122
13. Kovacs MJ, Rodger M, Anderson DR et al (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial. Ann Intern Med 138:714-719
14. Krahn AD, Healey JS, Simpson CS et al (2009) Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. Heart Rhythm 6:1276-1279
15. Lim W, Dentali F, Eikelboom JW et al (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684
16. Lip GY, Edwards SJ (2006) Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 118:321-333
17. Mant J, Hobbs FD, Fletcher K et al (2007) Warfarin versus aspirin for stroke prevention in atrial fibrillation in the elderly community population: the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA), a randomised controlled trial. Lancet 370:493-503 (Pubitemid 47212371)
18. Nutescu EA (2007) ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. Am J Health Syst Pharm 64:2281-2291
19. O'Donnell MJ, Kearon C, Johnson J et al (2007) Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146:184-187
20. Peng YG, Eikelboom JW, Tenni P et al (2004) Renal function, peak anti-Xa levels and enoxaparin dosing. J Pharm Practice Res 34:14-17
21. Poli D, Antonucci E, Grifoni E et al (2009) Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 101:367-372
22. Raschke RA, Gollihare B, Peirce JC (1996) The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 156:1645-1649
23. Rash A, Downes T, Portner R et al (2007) A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36:151-156
24. Rodger M, Kahn SR, Wells PS et al (2008) Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179:417-426
25. Rossol-Haseroth K, Vogel CU, Reinecke F et al (2002) Empfehlungen zur Thromboembolieprophylaxe bei internistischen Patienten im Alter. Internist 43:1134-1147
26. Schulman S, Beyth RJ, Kearon C et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133:257S-298S (Pubitemid 351892969)
27. Schulman S, Eriksson H, Goldhaber SZ et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342-2352
28. Soto-Cárdenas MJ, Pelayo-García G, Rodríguez-Camacho A et al (2008) Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med 22:965-968
29. Torn M, Bollen WL, van der Meer FJ et al (2005) Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 165:1527-1532
30. Weill-Engerer S, Meaume S, Lahlou A et al (2004) Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 52:1299-1304